Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 33,041 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Conditions
Hypercholesterolemia
Interventions
Colesevelam Hydrochloride, Ezetimibe, Simvastatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more
Completed Phase 4 Interventional Results available

Developing New Clinical Management Strategies

NCT02082392
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions
REGN7999, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Conditions
Healthy Subjects
Interventions
Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Alzheimers Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Completed Not applicable Interventional Accepts healthy volunteers

Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility

NCT03286764
Conditions
Enhancement of the ADR During Colonoscopy
Interventions
Peppermint Oil, Distilled water
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Gynecologic Cancer
Interventions
Lidocaine Bolus Infusion, QL block, Saline Bolus Infusion, Simulated QL block
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Conditions
Pain
Interventions
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min, Placebo Comparator: .9 normal saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Achondroplasia
Interventions
Navepegritide, Placebo for Navepegritide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
0 Years to 2 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Saint Paul, Minnesota • Houston, Texas • Madison, Wisconsin
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Completed Not applicable Interventional Results available

Non-Invasive Brain Stimulation and Substance Use

NCT03122587
Conditions
Substance Use Disorders
Interventions
Transcranial Alternating Current Stimulation at 10 Hz, Transcranial Alternating Current Stimulation at 40 Hz, Active sham transcranial alternating current stimulation
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
112
States / cities
Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more
Completed Not applicable Interventional Results available

Alternative Options to Minimize Niacin-Induced Flushing

NCT00895193
Conditions
Hypercholesterolemia, Flushing
Interventions
Apple pectin, Aspirin 325 mg, Placebo
Other · Drug
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 1Phase 2 Interventional Results available

Medications Development for Drug Abuse Disorders

NCT01188421
Conditions
Opioid Related Disorders, Opioid Dependence, Opioid Addiction
Interventions
Buprenorphine/naloxone, Clonidine, Tramadol ER
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3461767 in Healthy Participants

NCT04352114
Conditions
Healthy
Interventions
LY3461767 - SC, LY3461767 - IV, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Conditions
Postoperative Pain, Acute
Interventions
Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge, Sham Treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional

Prebiotic in Preterm Infants

NCT03306316
Conditions
Preterm Infant, Development, Infant, Nutrition
Interventions
Prebiotic, Dextrose Control
Dietary Supplement
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
7 Days to 10 Days
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Conditions
Post Operative Pain
Interventions
Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Damascus, Maryland